A Phase 1/2a Study of BMS-986253 (HuMax-IL8) in Combination With Nivolumab in Advanced Cancers
Phase of Trial: Phase I/II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs HuMax IL8 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 30 Nov 2018 Planned number of patients changed from 260 to 280.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 13 Feb 2018 Status changed from not yet recruiting to recruiting.